Skip to main content
. 2023 Mar 6;15:1137197. doi: 10.3389/fnagi.2023.1137197

Figure 2.

Figure 2

Kaplan–Meier curves for the cumulative hazard of Alzheimer’s disease with a 2 defined daily dose (DDD)-year interval by blood–brain barrier (BBB)-crossing angiotensin II receptor blockers (ARBs).